ClinVar Miner

Submissions for variant NM_000080.4(CHRNE):c.794C>T (p.Pro265Leu)

dbSNP: rs759226183
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000420519 SCV000521106 likely pathogenic not provided 2023-01-06 criteria provided, single submitter clinical testing Published functional studies demonstrate a damaging effect, as kinetic analysis showed P265L prolongs burst open duration 2-fold by slowing the rate of channel closing (Ohno et al., 1997); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 32721234, 34426522, 31589614, 9158150)
Invitae RCV000698763 SCV000827448 pathogenic Congenital myasthenic syndrome 4A 2023-11-27 criteria provided, single submitter clinical testing This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 265 of the CHRNE protein (p.Pro265Leu). This variant is present in population databases (rs759226183, gnomAD 0.009%). This missense change has been observed in individual(s) with autosomal recessive congenital myasthenic syndrome (PMID: 9158150; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. This variant is also known as epsilonP245L. ClinVar contains an entry for this variant (Variation ID: 381628). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CHRNE protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects CHRNE function (PMID: 9158150). For these reasons, this variant has been classified as Pathogenic.
AiLife Diagnostics, AiLife Diagnostics RCV000420519 SCV002501820 likely pathogenic not provided 2021-08-13 criteria provided, single submitter clinical testing
Athena Diagnostics Inc RCV000420519 SCV002770942 likely pathogenic not provided 2022-11-21 criteria provided, single submitter clinical testing The frequency of this variant in the general population is consistent with pathogenicity (http://gnomad.broadinstitute.org). This variant appears to segregate with autosomal recessive congenital myasthenic syndrome in at least one family, however, the available information does not rule out segregation due to chance. In some published literature, this variant is referred to as c.734C>T (p.P245L). Computational tools predict that this variant is damaging.
Fulgent Genetics, Fulgent Genetics RCV002502514 SCV002786934 likely pathogenic Congenital myasthenic syndrome 4A; Congenital myasthenic syndrome 4C; Congenital myasthenic syndrome 4B 2022-03-03 criteria provided, single submitter clinical testing
Baylor Genetics RCV000698763 SCV004212577 likely pathogenic Congenital myasthenic syndrome 4A 2023-10-10 criteria provided, single submitter clinical testing
Mayo Clinic Laboratories, Mayo Clinic RCV000420519 SCV004224134 likely pathogenic not provided 2022-06-30 criteria provided, single submitter clinical testing PP1, PP3, PM2, PM3, PS3_moderate

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.